The Effect of Liraglutide on Body Weight in Obese Subjects Without Diabetes
Sponsored by Novo Nordisk A/S
About this trial
Last updated 8 years ago
Study ID
NN8022-1807
Status
Completed
Type
Interventional
Phase
Phase 2
Placebo
Yes
Accepting
18 to 65 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 16 years ago
What is this trial about?
This trial is conducted in Europe. The purpose of the 20-week trial is to investigate the
efficacy of liraglutide to induce body weight loss and the purpose of the extension is to
evaluate the long term safety and tolerability of liraglutide.
Trial has the following trial periods: A 20-week randomised, double-blind,
placebo-controlled, six-armed parallel-group, multi-centre, multinational trial with an
open label orlistat comparator arm followed by an 84 week extension period.
What are the participation requirements?
Inclusion Criteria
- Body Mass Index (BMI) greater than or equal to 30.0 or lesser than or equal to 40.0 kg/m2
- Stable body weight (less than 5% selfreported change within the last 3 months)
Exclusion Criteria
- Obesity induced by drug treatment
- Use of approved drugs for weight lowering intervention (e.g. orlistat, sibutramin, rimonabant) within the last 3 months prior to entering trial
- Type 1 or type 2 diabetes